Drug Trial Radar · NCT05569239
Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,891
Actual
Start
Sep 8, 2025
Primary completion
May 18, 2026
Study completion May 18, 2026
Sponsor
- Lead sponsor
- OsivaxIndustry
- Sponsor type
- Industry
- First posted
- Oct 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 59 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The present study will evaluate the efficacy, immunogenicity and safety of one dose of OVX836 influenza vaccine 480μg, after intramuscular administration in healthy subjects aged 18-59 years.
Conditions
- Influenza
Interventions
OVX836 480µgBiological
One single administration intramuscularly at Day 1.
Saline SolutionBiological
One single administration intramuscularly at Day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- First occurrence of RT-PCR-confirmed influenza Type A symptomatic diseaseTime frame: During the whole study duration, up to maximum 10 months
Locations
16 sites in 4 countries. Site status is shown where the registry gives one.
Site BE-02
Antwerp, Belgium
Site BE-03
Antwerp, Belgium
Site BE-01
Ghent, Belgium
Site BE-04
Mechelen, Belgium
Site FI-12
Espoo, Finland
Site FI-08
Helsinki, Finland
Site FI-13
Jarvenpaa, Finland
FI-14
Kokkola, Finland
Site FI-11
Oulu, Finland
Site FI-15
Seinäjoki, Finland
Site FI-09
Tampere, Finland
Site FI-10
Turku, Finland
Site FR-05
Lyon, France
Site FR-07
Paris, France
Site FR-06
Rennes, France
Site DE-16
München, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.